ArticleOncoscience2014

Knock-down of BCL6 / STAT6 sensitizes primary B cell lymphoma cells for treatment with current therapeutic agents.

Marie-Therese Häberle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.